Zelira Therapeutics Ltd (ASX: ZLD) Share Price and News
Price
–
Movement
– ( )
(20 mins delayed)
52 Week Range
– - –
1 Year Return
Zelira Therapeutics Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$4.76 million
P/E Ratio
N/A
Dividend Yield
0.00%
Shares Outstanding
11.90 million
Earnings per share
-0.417
Dividend per share
N/A
Year To Date Return
-32.26%
Earnings Yield
N/A
Franking
-
Share Price
–
Day Change
– ( )
52 Week Range
– - –
Yesterday's Close
–
Today's Open
–
Days Range
– - –
Volume
–
Avg. Volume (1 month)
–
Turnover
–
Zelira Therapeutics Ltd (ASX: ZLD)
Latest News
Investing
Why Zelda Therapeutics Ltd shares jumped 10% higher today
Investing
Are the ASX pot stocks running out of puff?
Investing
Why these 4 ASX shares surged higher today
Investing
Aussie pot stocks are on the charge again
Investing
Here's Medlab Clinical Ltd's 'world first' plan to test cannabis on Sydney patients
Investing
Why these 4 ASX shares sank like stones today
Investing
Zelda Therapeutics Ltd shares rocket 23% higher
Investing
Aussie pot stocks are on fire again
Investing
Pot stocks are flying high: Here's what you need to know
Investing
Is the Australian pot stock sector party over?
Investing
Auscann Group Holdings Ltd shares are down 14% in a month
Investing
Australian pot stocks: August update
ZLD ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|
About Zelira Therapeutics Ltd
Zelira Therapeutics Ltd is a biotechnology company focused on developing a range of cannabinoid-based formulations for the treatment of various medical conditions in Australia. The company is involved in a human clinical trial program focused on insomnia, autism, and eczema; and a pre-clinical research program to examine the effect of cannabinoids in breast, brain, and pancreatic cancer.
ZLD Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 07 May 2025 | $0.40 | $-0.02 | -4.76% | 9,933 | $0.40 | $0.40 | $0.40 |
| 06 May 2025 | $0.42 | $0.04 | 10.53% | 12,497 | $0.38 | $0.42 | $0.37 |
| 05 May 2025 | $0.38 | $0.00 | 0.00% | 588 | $0.38 | $0.38 | $0.38 |
| 02 May 2025 | $0.38 | $0.00 | 0.00% | 571 | $0.38 | $0.38 | $0.38 |
| 01 May 2025 | $0.38 | $0.00 | 0.00% | 1,269 | $0.39 | $0.40 | $0.38 |
| 29 Apr 2025 | $0.38 | $0.03 | 8.57% | 682 | $0.38 | $0.38 | $0.38 |
| 28 Apr 2025 | $0.35 | $0.00 | 0.00% | 780 | $0.35 | $0.35 | $0.35 |
| 24 Apr 2025 | $0.35 | $0.00 | 0.00% | 1,058 | $0.35 | $0.35 | $0.35 |
| 23 Apr 2025 | $0.35 | $0.00 | 0.00% | 5,911 | $0.35 | $0.36 | $0.35 |
| 22 Apr 2025 | $0.35 | $-0.04 | -10.26% | 12,704 | $0.39 | $0.39 | $0.35 |
| 17 Apr 2025 | $0.39 | $0.00 | 0.00% | 332 | $0.39 | $0.39 | $0.39 |
| 16 Apr 2025 | $0.39 | $0.00 | 0.00% | 1,020 | $0.39 | $0.39 | $0.39 |
| 15 Apr 2025 | $0.39 | $-0.02 | -4.88% | 4,165 | $0.40 | $0.40 | $0.39 |
| 14 Apr 2025 | $0.41 | $-0.06 | -12.77% | 5,942 | $0.47 | $0.47 | $0.41 |
| 11 Apr 2025 | $0.47 | $0.00 | 0.00% | 1,156 | $0.47 | $0.47 | $0.47 |
| 10 Apr 2025 | $0.47 | $0.00 | 0.00% | 1,231 | $0.51 | $0.51 | $0.47 |
| 09 Apr 2025 | $0.47 | $-0.03 | -6.00% | 2,108 | $0.50 | $0.50 | $0.47 |
| 08 Apr 2025 | $0.50 | $0.04 | 8.70% | 4,060 | $0.46 | $0.50 | $0.46 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 17 Jan 2025 | Oludare Odumosu | Expiry | 110,334 | $69,510 |
As advised by the company. Lapsed because conditions have not been met.
As per announcement on 20/01/2025 |
| 17 Jan 2025 | Osagie Imasogie | Expiry | 335,094 | $211,109 |
As advised by the company. Lapsed because conditions have not been met.
|
| 13 Dec 2024 | Osagie Imasogie | Issued | 3,500,000 | $1,400,000 |
As advised by the company. USD,3,500,000 Convertible Notes, Issue
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Timothy (Tim) Ryan Slate | Company SecretaryNon-Executive Director | Dec 2016 |
Mr Slate provides accounting and secretarial advice to private and public companies. Mr Slate has over 15 years of experience in chartered accounting.
|
| Dr Oludare Odumosu | Managing Director | Dec 2019 |
Dr Odumosu has over 10 years of experience in corporate pharmaceutical business development, strategy & operational leadership including alliance management, Dr. Odumosu brings a unique combination of experiences from several academic, public health and life science organisations.
|
| Mr Osagie Imasogie | Non-Executive ChairmanNon-Executive Director | Dec 2019 |
Mr Imasogie has over 30 years of experience in the fields of law, finance, business management, healthcare and the pharmaceutical industry. He is a co-founder and the Senior Managing Partner of PIPV Capital, a Private Equity Firm that is focused on the Life Sciences vertical. Prior to co-founding PIPV Capital, Osagie conceptualised and established GlaxoSmithKline Ventures and was its founding Vice President.
|
| Mr Greg Blake | Executive Director | Feb 2023 |
Mr Blake has led the strategic development and commercialisation of a number of products across a range of therapeutic categories. Throughout his near 20 years working in healthcare Greg has built a solid foundation of knowledge across marketing and the entire commercial value chain.
|
| Dr Donna Gentile O'Donnell | Non-Executive Director | Jun 2023 |
Dr O'Donnell has led a diverse and successful career in health care, life sciences and public service concentrated in the Greater Philadelphia area. Donna was formerly a principal with O'Donnell Associates, her clients included non-profit organisations, universities, and life science companies, including Cephalon Pharmaceuticals.
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Mr Malik Majeed | 1,134,644 | 10.00% |
| Quincy Street Capital Llc | 456,622 | 4.02% |
| Mr Zoltan Kerekes | 393,168 | 3.46% |
| Osagie Imasogie | 393,168 | 3.46% |
| Sharri J Rochlin <Rochlin Family Resource A/C> | 393,168 | 3.46% |
| Sunset Capital Management Pty Ltd <Sunset Superfund A/C> | 383,725 | 3.38% |
| Ms Lisa Gray | 381,988 | 3.37% |
| Mera I Llc\C | 332,479 | 2.93% |
| Muller Ct Pty Ltd <Muller Super Fund A/C> | 312,126 | 2.75% |
| Mr Torsten M Geers <The Torsten M Geers Living A/C> | 307,454 | 2.71% |
| Mr Steve Shapiro | 302,571 | 2.67% |
| Mara Gordon | 252,242 | 2.22% |
| Mr Saul Shorr and Mrs Margaret Shorr | 151,285 | 1.33% |
| Dr Chanda Latrice Macias | 146,479 | 1.29% |
| Mera Ii Llc\C | 133,372 | 1.18% |
| Oludare Odumosu | 131,766 | 1.16% |
| Citicorp Nominees Pty Limited | 128,727 | 1.13% |
| Mr Daniel Hexter and Mrs Shannon Hexter | 103,389 | 0.91% |
| Geers Egag Llc | 85,715 | 0.76% |
| Connie H Katz and Samuel P Katz | 78,063 | 0.69% |